Screening method for therapeutic agents for Charcot-Marie-Tooth disease and self-differentiation motor neurons used therefor

A technique of motor neuron and screening method, applied in the field of preparation of induced pluripotent stem cells, can solve the problems of drug selection limitation and difference

Inactive Publication Date: 2016-01-20
SAMSUNG LIFE PUBLIC WELFARE FOUND +1
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Responses to drugs vary widely in CMT patients, so drug selection is limited because symptoms vary among CMT patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Screening method for therapeutic agents for Charcot-Marie-Tooth disease and self-differentiation motor neurons used therefor
  • Screening method for therapeutic agents for Charcot-Marie-Tooth disease and self-differentiation motor neurons used therefor
  • Screening method for therapeutic agents for Charcot-Marie-Tooth disease and self-differentiation motor neurons used therefor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Example 1: Isolation of CMT Patient-Derived Cells by Skin Biopsy

[0082] Skin biopsy is a safe, less invasive and economical method for pathological diagnosis of skin lesions. Under the approval of the institutional review board, the present inventors interviewed CMT2F patients exhibiting S135F or P182L mutations in the HSP27 gene as well as normal volunteers (Ewha Womans University Mokdong Hospital, Korea). To perform skin biopsy, local anesthesia was given to normal volunteers and CMT patients, and skin biopsy was performed by using a punch with a 4 mm diameter roundblade. Skin tissue obtained by skin biopsy was loaded in DMEM supplemented with: 10 mg / ml type IV collagenase (Invitrogen, USA), 50 U / ml dispase (Roche) and 0.05% trypsin / EDTA, followed by incubation at 37° C. The reaction was carried out for 40 minutes. The resulting cell suspension was filtered through a nylon cell strainer (passing particles up to 70 [mu]m in size). The resulting fibroblasts were cu...

Embodiment 2

[0087] Example 2: Preparation of induced pluripotent stem cells (iPSC) and embryoid bodies derived from CMT patients

[0088] Inducing the development of iPSCs derived from CMT patients

[0089] To prepare iPSCs for neuronal differentiation from fibroblasts obtained from CMT patients by skin biopsy in Example 1, Sendai protein containing 4 transcription factors (Klf4, Oct3 / 4, Sox2, and c-Myc) was used. Virus system (CellBiolabs, USA) was used to transfect fibroblasts from normal control group and CMT patients. The Sendai virus used did not insert into the host genome, instead it disappeared after several subcultures, suggesting that more stable iPSCs were obtained. The dose of Sendai virus was determined as MOI (multiplicity of infection)3. Cells were infected with Sendai virus overnight, and then the medium was replaced with DMEM supplemented with 10% FBS, followed by further culture for 6 days to stabilize the cells. Then, the cells were transferred to SNL feeder cells (...

Embodiment 3

[0111] Example 3: Inducing the differentiation of motor neurons derived from CMT patients and their differentiation efficiency

[0112] Differentiation of motor neurons from CMT2F-iPSCs

[0113] In order to use CMT2F-iPSCs as a peripheral neuropathy model, the figure 2 Differentiation from CMT2F-iPSCs to motor neurons was induced in the same manner as described in (AmorosoMW et al., JNeurosci2013;33:574-586)( figure 2 ).

[0114] Specifically, in order to induce embryoid body formation, CMT2F-iPSCs (S135F and P182L) or normal control WA09_hESCs induced in the same manner as described in Example 2 were divided into small clumps, and then supplemented with Suspension culture in ESC / iPSC medium (basic medium) for 2 days: 10 μM Y27632 (Rho-related kinase inhibitor, Tocris Bioscience, UK), 20 ng / ml bFGF (Invitrogen, USA), 10 μM SB435142 (Stemgent, USA), 0.2 μM LDN193189 (Stemgent , USA) and penicillin / streptomycin.

[0115] 3 days after the start of culture, the basal medium...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to induced pluripotent stem cells and a method for screening a therapeutic agent for Charcot-Marie-Tooth (CMT) disease by using motor neurons differentiated from the induced pluripotent stem cells. Particularly, the present invention enables the induced pluripotent stem cells to be prepared from a human fibroblast derived from a CMT patient, the effectiveness of a drug to be ascertained through the screening of a candidate material for a CMT therapeutic agent by using motor neurons differentiated from the induced pluripotent stem cells, and an autologous motor neurons to be prepared through the method for preparing the induced pluripotent stem cell, thereby being used for screening a patient personalized treatment drug and patient personalized treatment.

Description

technical field [0001] The present invention relates to a method for preparing induced pluripotent stem cells and a method for screening a therapeutic agent for Charcot-Marie-Tooth disease using autologous cells differentiated from the induced pluripotent stem cells. Background technique [0002] Charcot-Marie-Tooth disease (CMT), or hereditary motor and sensory neuropathy, is a defect or damage to motor and sensory neurons caused by mutations in specific genes. Hereditary peripheral neuropathies can be divided into three groups, namely, hereditary motor sensory neuropathy (HMSN), hereditary motor neuropathy (HMN), and hereditary sensory neuropathy (HSN). So, Hereditary Motor Sensory Neuropathy is one of them. Since the disease was first discovered by Charcot, Marie, and Tooth in 1886, it is named after them (ie, Charcot-Marie-Tooth disease), or simply CMT by their initials. In the late 20th century, Dyck et al. gave CMT another name, "hereditary motor sensory neuropathy (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/10C12N5/079C12Q1/68G01N33/15
CPCG01N2800/285C12N2500/02C12N2501/105C12N2501/115C12N2501/155C12N2501/727C12N2506/45G01N33/5058C12N5/0619C12N2501/13C12N5/0607G01N2500/10G01N2440/10
Inventor 金润泰崔炳玉禹昭妍金枝妍郑圣哲洪永彬朴晋模
Owner SAMSUNG LIFE PUBLIC WELFARE FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap